Almotriptan
From Wikipedia, the free encyclopedia
 |
|
|
Almotriptan
|
|
| Systematic (IUPAC) name | |
| N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine | |
| Identifiers | |
| CAS number | 181183-52-8 |
| ATC code | N02CC05 |
| PubChem | 123606 |
| DrugBank | APRD00169 |
| Chemical data | |
| Formula | C17H25N3O2S |
| Mol. weight | 335.465 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 35% |
| Metabolism | ? |
| Half life | 3-4 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Almotriptan (Axert®, Almogran®) is a triptan drug discovered by Almirall Prodesfarma and licensed to Ortho-McNeil for the treatment of migraine headaches. It is available in strengths of 6.25 and 12.5 mg as a tablet.
In the United States and Canada almotriptan is available only by prescription. The brand Almogran is used in Belgium, France, Germany, Italy, Portugal, Spain and the United Kingdom.
[edit] External links
- R&D page by Almirall Prodesfarma
- Axert Official homepage by Ortho-McNeil
- Axert Information Fact Sheet
| Triptans (N02CC) edit | ||
|---|---|---|
|
Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan |
||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
